PDK1 and pancreatic ductal adenocarcinoma: Pyruvate dehydrogenase kinases (PDKs), due to their key role in regulating metabolic flux linking the glycolytic pathway and tricarboxylic acid (TCA) cycle, represent relevant pharmacological targets for the design of a new class of anticancer drugs, especially against pancreatic ductal adenocarcinoma (PDAC), in which PDK1 was more widely expressed, facilitating increased anaerobic metabolism and apoptosis resistance under conditions of hypoxia and glucose deprivation.